BeOne Medicines ONC
SwitzerlandHealthcare · BiotechnologyUSD
435.20 USD (+19.6%)
27 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
BeOne Medicines Ltd. is a biopharmaceutical company that develops and commercializes innovative therapies, with a business model based on intensive R&D and high gross margins.
Key points
from its scores- ✓Strong growth9.5
- ✓Very solid balance sheet8.6
- ✓High-quality business7.7
- ✕Little or no dividend1.5
- ✕Demanding valuation3.1
AI analysis
bottom line, main risk, context and newsFundamentals are excellent and growth justifies the valuation, but the P/E of 65 and sector regulatory risk limit the margin of safety for new entries.
BeOne Medicines shows a solid financial profile: net cash (ND/EBITDA -2.84), 88.89% gross margin, and 29.6% revenue growth with earnings surging 166.7%. However, its valuation is demanding (P/E 65.12, EV/EBITDA 35.65), although the PEG of 0.77 suggests expected growth justifies the multiple. The main risk is regulatory, inherent to the biotech sector.
The main risk is dependence on regulatory approvals and patent protection to sustain 29.6% revenue growth and the demanding valuation (P/E 65.12); a clinical trial setback or adverse regulatory decision would have a material impact.
Context and risks
Company domiciled in Switzerland with moderate governance/regulatory risk. As a biotech, its valuation depends on regulatory approvals and patent protection, adding a specific business model risk not captured by financial metrics.
Is BeOne Medicines stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 145% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 65.1 | 26.7 | +144% |
| EV / EBITDA | 35.6 | 14.5 | +146% |
| Price / book | 8.0 | 4.1 | +94% |
| Price / sales | 6.8 | 3.4 | +98% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.1 out of 10 (median for Healthcare: 4.7).
Average analyst target: 435.20 USD, +19.6% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 7.7 (sector 5.5), Growth 9.5 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 65.1
- Forward P/E
- 35.5
- EV / EBITDA
- 35.6
- Price / book
- 8.0
- Price / sales
- 6.8
- PEG
- 0.77
- Market cap
- 41.4B USD
- Enterprise value
- 38.2B USD
Profitability
- ROE
- 14.7%
- ROA
- 7.5%
- ROIC (approx.)
- 16.1%
- Gross margin
- 88.9%
- Operating margin
- 19.1%
- Net margin
- 10.7%
- Free cash flow
- 879.0M USD
- FCF yield
- 2.1%
- Cash conversion
- 82%
Solvency
- Total debt
- 2.0B USD
- Net debt
- −3.0B USD
- Cash
- 5.1B USD
- EBITDA
- 1.1B USD
- Net debt / EBITDA
- −2.84
- Debt / equity
- 39.61
- Current ratio
- 3.40
- Quick ratio
- 2.91
Growth
- Revenue growth
- +29.6%
- Earnings growth
- +166.7%
- EPS (TTM)
- 5.59 USD
- EPS (forward)
- 10.26 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.61
- Analyst consensus
- Strong buy (27)
- Target price
- 435.20 USD
- 52-week range
- 253.95 – 385.22
Recent news
All ONC news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about BeOne Medicines
Is BeOne Medicines stock cheap or expensive?
On P/E and EV / EBITDA, it trades 145% above the Healthcare median on average. Valuation score: 3.1 out of 10 (median for Healthcare: 4.7). Average analyst target: 435.20 USD, +19.6% versus the price. This is not investment advice.
What score does BeOne Medicines get on MeridIAn Screener?
It scores 6.3 out of 10, rank 758 of 2,130 (better than 63% of the companies analysed). Its strongest category is Growth (9.5) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is BeOne Medicines's P/E ratio?
Its P/E is 65.1: the share price equals 65.1 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 35.5.
How much is BeOne Medicines worth on the stock market?
Its market capitalisation is 41.4B USD and its enterprise value, debt included, is 38.2B USD.
How much debt does BeOne Medicines have?
It has more cash than debt: net cash of 3.0B USD.
Does BeOne Medicines pay a dividend?
It pays no dividend, or almost none.
How has BeOne Medicines stock performed over the last year?
It has risen 13.7% over the last year, excluding dividends. Over the last 52 weeks it has traded between 253.95 and 385.22 USD. Past performance does not guarantee future results.
What do analysts think of BeOne Medicines?
27 analysts cover it; their average recommendation is “Strong buy” and their average target is 435.20 USD (+19.6% versus the price). It is an estimate, not market data.